Amwins Group Benefits works with brokers to help their clients navigate the future of gene therapy by empowering them to implement smart, practical and complete risk-management programs and strategies. We bring unrivaled knowledge and expertise to our retail partners by providing meaningful solutions that protect employers as they face the ever-evolving and complex gene-therapy landscape.
Human gene therapy aims to change a gene’s expression or the biological characteristics of living cells for treating or curing disease. According to the FDA, there are 32 cellular and gene therapies in the market today and seven to 10 additional approved treatments predicted by next year. Current treatment costs range between $850,000 and $3,500,000 and are expected to continue to rise as more approved gene-therapy treatments hit the market.
The Amwins Gene Therapy Solutions program currently provides coverage for three Food and Drug Administration (FDA) approved treatments that deliver curative or life-altering solutions for hereditary blindness and spinal muscular atrophy :